PRINCETON, N.J.--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services welcomed the appointments of Ilan Kaufthal as Senior Advisor, and Ronald Gold, Steven Klosk, and Chetan Jain to its Board of Directors. Ilan, Ron, Steve and Chetan will provide strategic support to accelerate the growth of NJ Bio to be the largest CRO in the USA to offer highly specialized bioconjugation, custom synthesis, flow chemistry, process development, and GMP services.
“We are excited to welcome Ilan, a seasoned investor, banker, and senior corporate executive to NJ Bio as our senior advisor. Ilan is the Chairman of the Board at East Wind Advisors. He brings over 30 years of experience in the financial sector and has held senior executive level positions at Irving Place Capital, Bear, Stearns & Co, and Schroders & Co and is currently Chairman of IDB Bank NY and serves on several boards at Tronox Ltd., Macsteel Ltd., Jerusalem Venture Partners Media Fund, American Friends of Bezalel, Board of Visitors at Columbia University Medical Center and is a Trustee of the Russell Berrie Foundation. We are confident that with Ilan’s financial acumen, NJ Bio will be able to grow into a powerhouse service provider,” said Nareshkumar Jain, Ph.D., President and CEO of NJ Bio.
NJ Bio has appointed three veteran pharmaceutical executives, Ron Gold, Steven Klosk, and Chetan Jain to its Board of Directors. Ron, a serial entrepreneur, is currently the Founder, CEO, and Chairman of the Board at Leading Pharma, and has over 30 years of experience in all aspects of the generic business. Prior to founding Leading, Ron was Founder, President and COO of Rising Pharma which was sold to Aceto Corporation (ACET). Steve is a pharma services veteran with nearly 30 years of experience in the CDMO space. He recently retired from Cambrex Corporation, where he was CEO for twelve years, after leading its sale to Permira, a global private equity firm at an enterprise value of approximately $2.5B. Under Steve’s leadership, Cambrex became a leading fully integrated supplier of drug substance, drug product, and testing services for the entire life cycle of innovator and generic pharma products. Cambrex has twelve manufacturing and R&D sites in the US and Europe with over 2000 employees. He is also on the Board of Directors of Recipharm, a leading European-based pharmaceutical CDMO and Caladrius Biosciences a publicly traded cell therapy drug development biotech company. Chetan, also a serial entrepreneur with over 20 years of experience in the pharmaceutical industry, is the Founder & CEO of Trichem, a differentiated sourcing partner and flagship company for its portfolio of Active Pharmaceutical Ingredients (APIs) and intermediates for global pharmaceutical companies and Chemistry & Health LLP (C & H). Trichem invests in start-up companies in the US and India. Trichem has 35 principals spanning Europe and Southeast Asia, a customer base of over 175 companies for US, EU, and other regulated markets, and has a distribution arm, domestic & ROW manufacturing, and marketing of APIs arm.
Drawing on the amalgamated industry experiences of Ron, Steve, and Chetan, NJ Bio expects to significantly increase its resources and capabilities to deliver high value services to its clients and become the leading specialized and differentiated CRO and CDMO in the US.
For additional information, visit www.njbio.com.
